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ABSTRACT
Introduction Maintaining independence is a primary 
goal of community health and care services for older 
people, but there is currently insufficient guidance about 
which services to implement. Therefore, we aim to 
synthesise evidence on the effectiveness of community- 
based complex interventions to sustain independence 
for older people, including the effect of frailty, and group 
interventions to identify the best configurations.
Methods and analysis Systematic review and network 
meta- analysis (NMA). We will include randomised 
controlled trials (RCTs) and cluster RCTs of community- 
based complex interventions to sustain independence 
for older people living at home (mean age ≥65 years), 
compared with usual care or another complex intervention. 
We will search MEDLINE (1946 to September 2020), 
Embase (1947 to September 2020), CINAHL (1981 to 
September 2020), PsycINFO (1806 to September 2020), 
CENTRAL and clinical trial registries from inception to 
September 2020, without date/language restrictions, and 
scan included papers’ reference lists. Main outcomes 
were: living at home, activities of daily living (basic/
instrumental), home- care services usage, hospitalisation, 
care home admission, costs and cost effectiveness. 
Additional outcomes were: health status, depression, 
loneliness, falls and mortality. Interventions will be coded, 
summarised and grouped. An NMA using a multivariate 
random- effects model for each outcome separately 
will determine the relative effects of different complex 
interventions. For each outcome, we will produce summary 
effect estimates for each pair of treatments in the 
network, with 95% CI, ranking plots and measures, and 
the borrowing of strength statistic. Inconsistency will be 
examined using a ‘design- by- treatment interaction’ model. 
We will assess risk of bias (Cochrane tool V.2) and certainty 
of evidence using the Grading of Recommendations 
Assessment, Development and Evaluation for NMA 
approach.
Ethics and dissemination This research will use 
aggregated, anonymised, published data. Findings will 
be reported according to Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses guidance. They 
will be disseminated to policy- makers, commissioners and 
providers, and via conferences and scientific journals.
PROSPERO registration number CRD42019162195.
INTRODUCTION
Global population projections indicate that 
older people are the fastest growing demo-
graphic, with the percentage of people aged 
65 years and over expected to almost double 
by 2050,1 and similar projections for devel-
oped countries such as the UK.2 Given this 
success of increasing lifespan, current policy 
and initiatives such as the WHO’s Decade 
of Healthy Ageing emphasise increasing the 
Strengths and limitations of this study
 ► This will be the first systematic review with network 
meta- analysis (NMA) comparing the effectiveness of 
community- based complex interventions to sustain 
independence for older people, including the effect 
of frailty and pre- frailty.
 ► A careful process to group interventions, including 
summarising each intervention with the Template 
for Intervention Description and Replication, will 
produce an analysis that is transparent and relevant 
to policy- makers, commissioners and providers.
 ► In addition to the direct treatment effects, indirect 
treatment effects will be analysed using a random- 
effects NMA allowing us to compare different ser-
vice models with each other.
 ► Summary of findings tables developed using 
the Grading of Recommendations Assessment, 
Development and Evaluation approach for NMA will 
provide an accessible assessment of the certainty 
and size of treatment effects.
 ► The review is likely to be limited by lack of detail 
about the experimental conditions and wider care 
system in some trials, and the lack of consistent 
outcome measures.
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number of years lived in good health.3 4 This focus on 
sustaining health is crucial for enabling people to realise 
their strong preference for living with independence 
within a community.5 Additionally, older people are core 
users of health and care services, so the ageing population 
demographic has profound implications for service plan-
ning and delivery. However, there is currently insufficient 
guidance for policy- makers, commissioners and providers 
about which community services should be implemented.
Frailty is an especially problematic feature of popula-
tion ageing, with increased risk of losing independence, 
hospitalisation, care home admission and mortality.6 In 
the UK, around 10% of people aged 65 years and over 
have frailty, rising to around 50% of people aged over 
85 years.7 UK NHS expenditure increases considerably 
with advancing age, with a threefold increase for people 
aged over 70 years.8 UK social care expenditure for older 
people is expected to rise to £12.7 billion by 2022.9 Extra 
annual cost to the healthcare system per person was 
£561.05 for mild, £1208.60 for moderate and £2108.20 
for severe frailty with reference to 2013/2014 UK costs.10 
This estimates a total additional cost of £5.8 billion per 
year across the UK.10 These findings are mirrored in 
other developed countries.
There is a critical evidence gap regarding which 
community- based interventions are clinically and cost 
effective for older people, including those living with 
frailty and pre- frailty. This evidence gap means that 
there is considerable uncertainty regarding the appro-
priateness of interventions and how they should best 
be configured and commissioned. Previous systematic 
reviews and meta- analyses (MAs) have reported evidence 
for clinical and cost effectiveness of community- based 
complex interventions for reducing hospital admission, 
nursing home admission, falls and functional decline 
in older people.11–13 However, previous reviews have 
not used network meta- analysis (NMA) to summarise 
whether different types of interventions have differen-
tial effects on outcomes, limiting usefulness for policy- 
makers, health and social care commissioners and 
providers. Moreover, few systematic reviews have investi-
gated such interventions delivered outside of the home 
environment. A landmark 2008 systematic review and 
MA summarised evidence from 89 trials, including 97 984 
people.11 The review reported that, in general, complex 
interventions provided in the community are effective 
for older people but lacked detail about what types of 
complex care improve outcomes, and does not include 
studies published over the last decade, which are poten-
tially influential. This review only considered frailty in 
relation to one intervention (comprehensive geriatric 
assessment) and used a disability- based, non- validated 
definition of frailty to categorise trials. Standard MA tech-
niques were used to synthesise the evidence.
Recognising that research evidence, understanding of 
frailty and MA methods have advanced considerably in the 
last decade, the review requires a contemporary update 
to identify how interventions might best be configured 
to improve outcomes and inform commissioning and 
delivery of evidence- based services.
Specific review questions are:
1. Do community- based complex interventions to sus-
tain independence in older people increase living at 
home, independence and health- related quality of 
life?
2. Do community- based complex interventions to sus-
tain independence in older people reduce home- care 
requirement, depression, loneliness, falls, hospitalisa-
tion, care home admission, costs and mortality?
3. How should interventions be grouped for network 
meta- analysis (NMA)?
4. What is the optimal configuration of community- based 
complex interventions to sustain independence in old-
er people?
5. Do intervention effects differ by frailty level (not frail, 
pre- frailty; frailty)?
Objectives
The overall aim of this systematic review is to synthe-
sise evidence on the effectiveness of community- based 
complex interventions to sustain independence in older 
people, including the effect of frailty and pre- frailty, and 
group interventions to identify the best configurations. 
For this systematic review, we define sustaining indepen-
dence to mean maintaining or improving independence 
in activities of daily living (washing, dressing, grooming, 
toileting, walking, preparing meals, doing housework, 
managing finances, assisting others, etc), but not only 
one of these specific activities (eg, walking only). The 
specific objectives are as follows:
1. To identify randomised controlled trials (RCTs) 
and cluster RCTs (cRCTs) of community- based com-
plex interventions to sustain independence in older 
people.
2. To synthesise evidence of their effectiveness for key 
outcomes in an MA of study- level data.
3. To identify key intervention components and study- 
level frailty to inform groupings for NMA and meta- 
regression.
4. To compare effectiveness of different intervention 
configurations using NMA.
5. To investigate the impact of frailty and pre- frailty using 
meta- regression.
METHODS AND ANALYSIS
This protocol is reported in accordance with the reporting 
guidance provided in the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses Protocols (PRIS-
MA- P) statement and PRISMA- NMA reporting guide-
lines.14 15
Eligibility criteria
We will select studies according to their design and the 
PICO criteria: participants, intervention, comparator and 
outcome(s) of interest.
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Study design
RCTs and cRCTs are eligible. Where only one unit of 
randomisation (an individual or cluster) is allocated to 
an arm of a trial, we will exclude the trial as the treatment 
effect is completely confounded with the unit. We accept 
minimisation as a method of sequence generation, in 
keeping with the Cochrane risk of bias (RoB) guidance. 
Crossover trials are also eligible; however, we will only use 
outcome data from the pre- crossover period.
Participants (population)
Older people living at home (mean age of participants: 65 
years or older). We will exclude trials of residents of care/
nursing homes as these are the subject of other large- scale 
reviews.16 17 If not all participants are living at home, we 
will only include the trial if data can be extracted specifi-
cally for these participants.
Intervention
Aligned with our focus on community- based complex 
interventions, trials will be considered eligible if:
 ► The intervention is both initiated and mainly provided 
in the community.
 ► The intervention includes two or more interacting 
components (intervention practices, structural 
elements and contextual factors).
 ► The intervention is targeted at the individual person, 
with provision of appropriate specialist care.
 ► A focus of the intervention is sustaining (maintaining 
or improving) the person’s independence.
A broad range of interventions will potentially be 
eligible, which may differ in terms of how the service is 
organised and what is done to or for the older person. 
Interventions may meet our criteria for including two 
or more interacting components by including multiple 
discrete practices, such as exercise sessions and nutri-
tional advice. Other eligible interventions could include 
one practice that interacts with other structural elements 
such as being reliant on general practice or other services; 
or interaction with contextual factors by being substan-
tially tailored to the person’s physical and social environ-
ment. Examples would include comprehensive geriatric 
assessment or rehabilitation interventions.
Interventions that would not be considered eligible for 
inclusion are as follows:
 ► The intervention is either not initiated, or not mainly 
provided, in the community, or neither. For example, 
interventions delivered in outpatient, day hospital, 
inpatient and intermediate (post- acute) care settings.
 ► The intervention includes only one discrete compo-
nent (intervention practices, structural elements and 
contextual factors) such as a drug, treadmill training, 
yoga, provision of information, cataract surgery, 
hearing aid, medication review and nutritional 
supplements.
 ► The intervention is not targeted at the individual 
person, with provision of appropriate specialist care, 
for example, general staff education (not training in 
a patient- level intervention), practice- level reorgan-
isation, operational, managerial or IT interventions, 
public health messages.
 ► A focus of the intervention is not sustaining (main-
taining or improving) independence in activities of 
daily living (ADL). For example, interventions that 
primarily address cognitive deficits, mood disorders, 
or both will be excluded, unless they also aimed to 
improve overall independence.
 ► Condition- specific interventions, for example, case 
management for older people with diabetes, chronic 
obstructive pulmonary disease or depression.
 ► Interventions in which the primary focus is falls 
prevention as this evidence is already well synthesised, 
including in a recent NMA.18 Nonetheless, falls will be 
a key additional outcome in this review.
Comparator
Usual care, ‘placebo’ or attention control, or a different 
complex intervention meeting our criteria are eligible 
comparators.
Outcome(s)
Studies will be included where outcome data were 
recorded at a minimum 24- week timepoint. For all 
outcomes of interest, data will be extracted and catego-
rised for three timepoints: around 6 months, around 12 
months and around 24 months.
Main outcomes
 ► The main outcomes are living at home (defined 
either as a reported trial outcome, or the inverse of 
care home admission and mortality if reported sepa-
rately); independence in ADL (basic/instrumental); 
home- care services (non- healthcare professional) 
usage; hospitalisation; care home admission; costs; 
and cost effectiveness.
Additional outcomes
 ► The additional outcomes are health status/health- 
related quality of life, depression, loneliness, falls and 
mortality.
This update to the landmark 2008 systematic review and 
MA by Beswick and colleagues11 refines the criteria used 
by that review, which will lead to the exclusion of some 
of their included studies; we recount these differences 
here. We will exclude falls prevention studies as a recent 
NMA has been conducted in that area.18 Our criteria 
exclude interventions that are initiated in hospital and 
those conducted in outpatient settings, to ensure the 
interventions are firmly placed in the community. We will 
also exclude interventions in residential care settings, as 
these are already the subject of large- scale reviews, and 
the different settings provide different opportunities and 
challenges for intervening. Finally, we will exclude studies 
without an intervention targeted at the older person, for 
example, financial incentives for general practitioners, 
for consistency within our NMA.
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Search strategy
Search strategies have been developed and tested through 
an iterative process by an experienced medical informa-
tion specialist in consultation with the review team. We 
will search the following databases from inception:
 ► Cochrane Central Register of Controlled Trials 
(CENTRAL; issue 9 of 12, September 2020).
 ► MEDLINE Ovid (1946–September 2020).
 ► Embase and Embase Classic Ovid (1947–September 
2020).
 ► CINAHL EBSCO (1981–September 2020).
 ► PsycINFO Ovid (1806–September 2020).
We will also search trial registers ( ClinicalTrials. gov and 
the International Clinical Trials Registry) from inception 
and scan reference lists of included papers. Publication 
status, date or language restrictions will not be used, and 
translation will be arranged as necessary throughout the 
process. A draft search strategy for MEDLINE is provided 
in the online supplemental appendix A. A PRISMA flow 
chart will be presented showing the process of study selec-
tion (online supplemental figure S1).14
Study selection
Following deduplication, search results will be imported 
into the Rayyan web application (https:// rayyan. qcri. 
org/). Two researchers will independently assess the title 
and abstract of each record. We will obtain full text arti-
cles for all potentially eligible trials. Study selection will 
be conducted by two researchers with guidance from the 
project management group (PMG), and disagreements 
will be resolved by consensus discussion involving the 
PMG. We will contact study authors if further information 
is required.
Data collection process
Two researchers will independently extract data using a 
piloted data extraction form in a purpose- built Micro-
soft Access database. Characteristics of included and 
excluded studies’ tables will be produced in Review 
Manager (RevMan) V.5.4. Summary of findings tables 
will be produced in Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) Pro.19
Intervention grouping
We will group interventions for NMA in a three- stage 
process.
1. We will use the Template for Intervention Description 
and Replication (TIDieR) framework to summarise re-
ported interventions (including comparators).20 The 
TIDieR framework includes 12 key items, including 
the why, what, who provided, how, where, when and 
how much of the intervention, including the broader 
healthcare context.
2. We will complete a content analysis of the summarised 
interventions using the TIDieR framework in nVivo 
V.12 to inform provisional groupings.21
3. We will develop provisional intervention groupings 
based on the service organisation or structure (eg, 
team structure), key patient care processes (eg, assess-
ment and follow- up) and specific patient care interven-
tions (eg, exercise, ADL practice and relaxation). The 
intervention types will become the nodes in the NMA.
Assessment of frailty
We anticipate that a range of validated instruments and 
operationalised measures will be used to identify pre- 
frailty and frailty in included trial populations of some 
studies. Examples of such frailty measures include: the 
use of the Fried phenotype model, the Tilburg Frailty 
Indicator, Groningen Frailty Indicator, Study of Osteopo-
rotic Fractures criteria, Chinese Canadian study of health 
and ageing clinical frailty scale, Hebrew Rehabilitation 
Center for Aged Vulnerability Index, Vulnerable Elders 
Survey, and Brief frailty measure derived from the Cana-
dian study of health and ageing or a formally produced 
Frailty Index.22 We will classify the trial population in 
accordance with the frailty measure, so long as it is devel-
oped or validated according to the modern meaning of 
frailty and not as a generic term for being old or disabled. 
We will report methods used for each trial, including cut- 
off points for identification of pre- frailty and frailty.
We also anticipate that many studies will not formally 
have described study populations in terms of frailty. In 
such circumstances, two reviewers with extensive clin-
ical academic frailty expertise (AC and JRFG) will inde-
pendently use the well- validated phenotype model as a 
framework to categorise study- level frailty profile (not 
frail, pre- frailty and frailty) of trial participants if the rele-
vant variables are reported.23 The model is based on five 
characteristics (weight loss; exhaustion; low energy expen-
diture; slow gait speed and low grip strength). Evidence 
of ≥3 indicates frailty, 1–2 pre- frailty and 0 not frail. In 
the remaining studies where neither a recognised frailty 
measure nor the variables needed to apply the frailty 
phenotype categorisation are reported, the two reviewers 
will independently attempt to classify the populations 
based on trial eligibility criteria and/or reported base-
line characteristics closely linked to frailty, including gait 
speed, hand grip strength, mobility, activity or disability 
levels. Any disagreements will be resolved by consensus.
In categorising study- level frailty, we recognise that 
trials may include participants across different frailty cate-
gories, so as well as ‘not frail’, ‘pre- frail’ and ‘frail’; our 
categories will also include ‘not frail and pre- frail’, ‘pre- 
frail and frail’ and ‘all’.
Our main analysis of the impact of frailty will only 
include trials that used a validated measure. Trials in 
which the reviewers allocated a study- level frailty level on 
the basis of eligibility criteria and/or baseline characteris-
tics will be examined in secondary analyses.
Intention to treat and missing data
If both per- protocol and intention- to- treat analyses are 
reported for a trial, we will prioritise intention- to- treat 
data.24 In all instances, we will report whether analysis 
was conducted on data that were complete, complete 
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after imputation or incomplete, and we will examine and 
report any material differences in results across these 
types. When results for main outcomes are missing for a 
trial, we will contact authors to request the missing data.
RoB within individual studies
Researchers will independently assess the RoB of 
each result of interest from each included trial, using 
Cochrane’s RoB 2—a revised tool for assessing RoB in 
randomised trials.24 For cRCTs, we will additionally assess 
identification/recruitment bias, and the other issues such 
as loss of clusters, detailed in version 6 of the Cochrane 
Handbook.25 For each domain in the RoB 2 tool, a 
judgement of high RoB, low RoB or some concerns will 
be made, then an overall risk- of- bias judgement will be 
reached for each assessed outcome, with any disagree-
ments resolved by consensus.
Summary measures
For each trial and each outcome separately, effect esti-
mates and confidence intervals (CIs) will be extracted 
comparing intervention and control groups. For contin-
uous outcomes, we aim to extract the intervention effect 
as mean differences. We will consider using standardised 
mean difference if different measures are used for similar 
constructs. For binary outcomes, we will calculate risk 
ratios (RRs) and odds ratios (ORs). For survival (time- 
to- event) outcomes, hazard (rate) ratios (HRs) will be 
extracted. Any details about non- proportional hazards 
will also be extracted. Outcomes at all timepoints will be 
recorded and grouped appropriately (around 6 months, 
around 12 months and around 24 months). Where 
effect estimates and/or CIs are not available, we will use 
other information (eg, p values, means for each group at 
follow- up, etc) to derive the information indirectly.
Unit of analysis issues
We will apply adjustment for trials that use cluster rando-
misation without adjusting standard errors.25 As intraclass 
correlations needed to make such correction are rarely 
reported, we will use values obtained from external litera-
ture for the outcome examined (or if these are not avail-
able, use a single plausible value and examine the impact 
of varying this value in sensitivity analysis).
Examination of potential effect modifiers
Treatment effect modifiers relate to methodological or 
clinical characteristics of the trials that influence the 
magnitude of treatment effects (on a given scale), and may 
include follow- up length, outcome definitions, trial quality 
(RoB), analysis and reporting standards (including risk of 
selective reporting) and the participant- level characteris-
tics (eg, leading to trial differences in case- mix variation, 
including frailty). When such effect modifiers are system-
atically different in trials making the same comparison(s), 
this manifests itself as between- study heterogeneity in 
treatment effects. When such effect modifiers are system-
atically different in the subsets of trials providing direct 
and indirect evidence about a particular comparison, this 
causes inconsistency (ie, disagreement between the direct 
and indirect evidence for that comparison) in the NMA.
Hence, before any analysis, the distribution of poten-
tial effect modifiers will be examined across the studies 
to inform inconsistency concerns (whether direct and 
indirect evidence in the NMA are likely to be coherent) 
and whether some trials should be removed to improve 
consistency. Clearly, such decisions will also be based on 
the inclusion and exclusion criteria for the project.
Data synthesis
We will meta- analyse the extracted effect estimates 
using modules within R and Stata, such as metafor, 
metan, mvmeta and network. Random- effects MAs 
will be conducted, to allow for potential between- study 
heterogeneity in each intervention effect.26 Restricted 
maximum likelihood (REML) estimation will be used 
to fit all the models, with 95% CIs derived using an 
approach to account for uncertainty in the estimate of 
heterogeneity (tau- squared), such as the Hartung- Knapp- 
Sidik- Jonkman approach.27 Initially for each outcome, 
we will perform a separate MA for each type of inter-
vention, to provide summary effectiveness results based 
only on direct evidence. We will summarise ORs and 
RRs for binary outcomes, pooled (standardised) mean 
differences for continuous outcomes and pooled HRs 
for survival outcomes. We will display forest plots, with 
study- specific estimates, CIs and weights, alongside the 
summary (pooled) MA estimates, 95% CI, and (if appro-
priate) a 95% prediction interval.
Network meta-analysis
An NMA will then be conducted (for each outcome sepa-
rately), using a multivariate random- effects MA frame-
work via the network module in Stata and using REML 
estimation (with CIs derived accounting for uncertainty 
of variance estimates).28 Nodes in the network will corre-
spond to each intervention group as outlined previously. 
The NMA framework allows both direct and indirect 
evidence to contribute toward each intervention effect 
(treatment contrast) via a consistency assumption.29 
The within- study correlation of multiple intervention 
effects from the same trial (ie, in multigroup trials) will 
be accounted for, and a common between- study variance 
assumed for all treatment contrasts in the network (thus 
implying a +0.5 between- study correlation for each pair of 
treatment effects). If possible, sensitivity to relaxing this 
assumption will be examined using model fit statistics. We 
will produce summary (pooled) effect estimates for each 
pair of treatments in the network, with 95% CI, and the 
borrowing of strength statistic to reveal the contributions 
of indirect evidence. For binary outcomes, if possible, 
we will do an NMA of both OR and RR, to check the 
robustness of conclusions to the choice of effect measure. 
Based on the results, the ranking of intervention types 
will be calculated using resampling methods, quantified 
by the probabilities of being ranked first, second, …, last, 
together with the mean rank and the Surface Under the 
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Cumulative RAnking curve, and will be presented with 
appropriate plots.
Assessment of inconsistency
The consistency assumption will be examined for each 
treatment comparison where there is direct and indirect 
evidence (seen as a closed loop within the network plot). 
This involves estimating direct and indirect evidence, and 
comparing the two.30–32 The consistency assumption will 
also be examined across the whole network using ‘design- 
by- treatment interaction’ models, which allow an overall 
significance test for inconsistency. If evidence of inconsis-
tency is found, explanations will be sought and resolved 
(eg, with consideration of the distribution of effect modi-
fiers; see earlier).
Examination of small-study effects
If there are 10 or more studies in an MA, funnel plots 
will be presented to examine small- study effects (poten-
tial publication bias). Egger’s, Peter’s and Debray’s test 
of asymmetry will be used for continuous, binary and 
survival outcomes, respectively.
Examination of frailty impact
MA results will initially be presented for all levels combined, 
then for frailty/pre- frailty where reported data permit. 
That is, a separate MA and NMA for each frailty type will 
be conducted. Indeed, this may also reduce any incon-
sistency (see above). We will also consider extending the 
MA and NMA models to a meta- regression, with frailty/
pre- frailty as a study- level categorical covariate allowing 
effects of frailty/pre- frailty to vary for each treatment 
effect, to quantify if intervention effects vary according to 
population- level frailty.
All analyses to examine frailty impact will initially be 
restricted to trials using a validated measure. Sensitivity 
analyses will (1) be restricted to trials using the pheno-
type model to identify pre- frailty/frailty as an internation-
ally established reference standard, (2) include trials that 
used either a validated or an operationalised measure of 
frailty, and (3) include all trials, including by study- level 
categorisation of frailty status.
Additional analyses
We will also run additional sensitivity analyses to present 
results of more recent evaluations, restricted to trials in 
the last 15 years. Meta- regression will be used to quan-
tify differences in summary effects between studies at low 
RoB and other studies, and between those with shorter 
and longer lengths of follow- up. A multivariate NMA will 
be considered to accommodate all outcomes simultane-
ously, to examine if conclusions remain the same after 
accounting for the correlation among outcomes.33 As 
mentioned, we will consider how relaxing the assumption 
of common between- study variances improves model fit.
Confidence in cumulative evidence
We will use the GRADE framework, adapted for NMA, 
to rate evidence quality.34–37 Our assessment of quality 
of treatment effects will enable generation of GRADE 
evidence profiles for our individual intervention group-
ings for each outcome separately.
The assessment of quality of treatment effects will 
include presentation and rating of the quality of direct and 
indirect treatment estimates separately and combined in 
NMA,36 with a focus on first- order loops for assessment of 
indirect treatment estimates. As we will include RCTs and 
cRCTs, the starting point will be a high- quality evidence 
rating. For each estimate of treatment effect, we will 
assess RoB, inconsistency, indirectness, imprecision and 
publication bias. We will make an overall judgement on 
whether the quality rating for each effect warrants down-
grading on the basis of limitations in each of the domains, 
aligned with GRADE guidance.37 We will not consider 
imprecision when rating the direct and indirect estimates 
to inform the combined NMA rating, aligned with recent 
guidance.34 Furthermore, in the presence of incoherence 
between direct and indirect estimates, we will assess the 
certainty of evidence of each estimate to guide whether 
or not the network estimate is downgraded.34
Patient and public involvement
Our established patient and public involvement Frailty 
Oversight Group (FOG) provides connections to the 
whole spectrum of older people, with a focus on those 
living with frailty. We have consulted our FOG throughout 
the development of this protocol and discussed plans 
in detail at quarterly meetings. A specific example of 
their influence is our selection of main and additional 
outcomes of importance for older people. We plan to 
involve FOG in our intervention grouping and dissemi-
nation of this review.
Timelines
Formal screening of search results began in January 
2020. Data extraction began in May 2020. RoB assessment 
and data synthesis have not yet begun. We are currently 
updating our searches (September 2020). The project is 
due to complete in October 2021.
ETHICS AND DISSEMINATION
Ethics approval is not needed as this systematic review will 
use aggregated, anonymised data that is available in the 
public domain.
This will be the first systematic review with NMA 
comparing the effectiveness of community- based 
complex interventions to sustain independence for older 
people, including the effect of frailty and pre- frailty. The 
review will use a detailed analysis to group the included 
interventions to identify the best configurations. Further-
more, it will also review the quality of evidence using 
the GRADE approach.36 We will disseminate the find-
ings widely through communication with healthcare 
providers, conference presentations and academic 
publications. We will adhere to PRISMA- NMA reporting 
guidelines.14 Hence, this systematic review will produce 
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transparent and accessible results that are of great rele-
vance and applicability for a wide audience, including 
policy- makers, commissioners, healthcare/social care 
professionals, older people and researchers working with 
an older population.
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